Eli Lilly and Company’s obesity medication, Zepbound, resulted in more significant weight reduction compared to Novo Nordisk’s Wegovy in a Phase 3b comparative clinical study. This information was detailed in an article featured in The New England Journal of Medicine as well as showcased at the European Congress on Obesity.

The 72-week SURMOUNT-5 trial found that adults with obesity or overweight with at least one related health condition — excluding those with diabetes — lost an average of 20.2% of their body weight on Zepbound compared to 13.7% on Wegovy.

Eli Lilly stated that the outcomes indicated a 47% higher relative weight loss with Zepbound, where participants lost an average of 50.3 pounds compared to 33.1 pounds for those using Wegovy.

Zepbound also outperformed Wegovy across all critical secondary endpoints.

Nearly 65% of Zepbound-treated participants achieved at least 15% weight loss, compared to 40.1% of those on Wegovy.

During the trial, participants using Zepbound experienced an average decrease in waist size of 18.4 cm, whereas those taking Wegovy had their waist measurements reduced by 13.0 cm on average.

The safety profile of Zepbound was in line with previous trials in the SURMOUNT program, with most adverse events being gastrointestinal in nature and typically mild to moderate.

The dropout rate because of adverse reactions stood at 6.1% for Zepbound and 8% for Wegovy.

In the Big One News report, the sentiment towards Eli Lilly was ‘bearish’ even with a high number of messages circulating about them.

Several retail investors shared their thoughts on the potential future value of the company’s stock; some wondered if the share price might climb as high as $500, whereas others predicted it could even hit $600 before the week concluded.

The negative sentiment arose against the backdrop of increased oversight on drug pricing.


Excitement in retail circles regarding healthcare stocks

surged late Sunday following President Donald Trump’s announcement that he plans to sign an executive order aimed at slashing prescription drug prices in the US by 30% to 80%.

Trump cited a “Most Favored Nation Policy” in a Truth Social post, saying it would align US drug prices with the lowest-paying country.

So far in 2025, Eli Lilly’s stock has dropped by 5.6%.

For updates and corrections, email newsroom[at]Big One News[dot]com.